Industry Experience

Senior Counsel

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Deputy General Counsel

Brookstone, Inc.

Product Counsel

Apple, Inc.

Jon handles complex transactions and agreements in the life sciences and technology industries. He guides life sciences clients through research and development, manufacturing and product licensing transactions with other commercial entities, as well as with academic research institutions. Jon has handled trans-border deals, negotiating and successfully completing product licenses involving European, Asian and U.S-based drug companies, including related supply agreements.

Jon also advises technology clients on complex software license and related support agreements, IT platform license and support agreements for drug development, healthcare services, database services and other applications.

experience +

experience –

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Senior Counsel

  • Handled legal matters for the company in many areas, including licensing biotechnology and software technologies and advising its clinical and manufacturing operations
  • Primary business attorney for one of Millennium’s key technology alliances
  • Helped to mentor and train Millennium’s contracts associates

Before Millennium, Jon served as Deputy General Counsel for Brookstone, where he helped develop systems for intellectual property protection for the company’s proprietary products. He also held the position of Product Counsel for Apple, serving as software and technical counsel for a variety of Apple product lines.

Jon started his legal career as a business associate in the Los Angeles office of Folger & Levin. Prior to attending law school, Jon worked for several years in the publishing industry.

Recent Client Work +

Recent Client WOrk –

  • ‍Collaboration agreement between Biogen and Proteostasis Therapeutics, Inc., for the development of drugs to combat Alzheimer’s and other neurodegenerative diseases (involved amendment of a pre-existing license agreement with Harvard University)
  • In-license of antibody screening and development platform by Biogen from Adimab, LLC
  • License and collaboration agreement between Taiwanese company PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. involving grant back from PharmaEngine to Merrimack of research, development and commercialization rights to an oncology drug candidate in exchange for milestones and royalties
  • Exclusive in-license by Taiwanese company PharmaEngine, Inc. from French company Nanobiotix, S.A. of Asian research, development and commercialization rights to nanotherapy oncology treatment
  • Expansion from Asia-only to worldwide of Japanese company Solasia Pharma K.K.’s exclusive license with ZIOPHARM Oncology, Inc. for research, development and commercialization of oncology product
  • Exclusive license from EMD Millipore, Inc. to Charles River Laboratories International, Inc. for use of EMD Millipore’s proprietary virus clearance technology
  • Supervision of Faber’s clinical trial contracting efforts for Portola Pharmaceuticals, Inc., including global Phase III APEX study of Portola’s lead Factor Xa inhibitor, betrixaban

Community +

Community –

Bar Admissions
  • ‍California
  • Massachusetts
  • Stanford Law School, J.D.,  with Distinction
  • Brown University, A.B., magna cum laude with Honors